Accueil > Votre projet > Innover > Outils en ligne > Bourse de technologies

Bourse de technologies

Retour

< Retour à la liste des résultats
Version française Version anlgaise	Enregistrer cette offre Signaler un problème

New anti-Leishmania pharmaceutical compounds
This invention concerns the use of nicotinamide, a form of vitamin B3 as a therapeutic antileishmanial agent. This molecule exhibits an anti‐parasitic activity, and acts in a synergistic manner when it is used in combination with other known antiparasitic molecules, both in vitro and in vivo.

Technical Description :
The development of new drugs to treat parasitic diseases (human and canine leishmaniasis, Chagas disease, sleeping sickness) is a considerable challenge. An IRD research team has revealed the antileishmanial activity of nicotinamide, one of the forms of the vitamin B3: - In vitro, at low doses, it inhibits the proliferation of parasites in their amastigote and promastigote forms, and at higher doses affects there viability. - It considerably improves the effectiveness of known antiparasitic molecules (antimony, amphotericin B) on the axenic and intracellular forms of the parasite’s amastigote stage. These results reveal a synergistic effect between nicotinamide and antiparasitics.

Potential applications :
Therapy or prophylaxis for parasitical diseases such as leishmanasis of pet animals, populations in developing countries and patients suffering from AIDS throughout the world.

Benefits :
The present obstacles to the use of most existing chemical formulations such as difficulty of administration, length of treatment, high cost and toxicity, and development of resistant strains, can partially be circumvented by this compound: - nicotinamide is a non toxic, low cost agent with good bioavailability; - the synergistic action between nicotinamide and other antiparasitic molecules would allow usual doses to be lowered thus minimising their side affects. Its non‐toxicity also makes it an ideal candidate for preventive approaches.

Development :
Effect on parasites in culture demonstrated.

Intellectual property :
-Technology protected by patent priority in the USA on the 19/07/04 and extended to Europe, Brazil and India (WO/2006/008082). - Available for licence and or collaborative research.

Partnership type :
Disponible pour licence et/ou recherche collaborative